Health Plans Lose Provigil Pay-For-Delay Class Cert Bid

A Pennsylvania federal judge on Monday refused to certify a class of health plans and others that ultimately paid for narcolepsy drug Provigil in an antitrust suit against Cephalon Inc., days after...

Already a subscriber? Click here to view full article